Extended antimicrobial treatment of bacterial vaginosis combined with human lactobacilli to find the best treatment and minimize the risk of relapses

Per-Göran Larsson, Erik Brandsborg, Urban Forsum, Sonal Pendharkar, Kasper Krogh Andersen, Salmir Nasic, Lennart Hammarström, Harold Marcotte, Per-Göran Larsson, Erik Brandsborg, Urban Forsum, Sonal Pendharkar, Kasper Krogh Andersen, Salmir Nasic, Lennart Hammarström, Harold Marcotte

Abstract

Background: The primary objective of this study was to investigate if extended antibiotic treatment against bacterial vaginosis (BV) together with adjuvant lactobacilli treatment could cure BV and, furthermore, to investigate factors that could cause relapse.

Methods: In all, 63 consecutive women with bacterial vaginosis diagnosed by Amsel criteria were offered a much more aggressive treatment of BV than used in normal clinical practice with repeated antibiotic treatment with clindamycin and metronidazole together with vaginal gelatine capsules containing different strains of lactobacilli both newly characterised and a commercial one (109 freeze-dried bacteria per capsule). Oral clindamycin treatment was also given to the patient's sexual partner.

Results: The cure rate was 74.6% after 6 months. The patients were then followed as long as possible or until a relapse. The cure rate was 65.1% at 12 months and 55.6% after 24 months. There was no significant difference in cure rate depending on which Lactobacillus strains were given to the women or if the women were colonised by lactobacilli. The most striking factor was a new sex partner during the follow up period where the Odds Ratio of having a relapse was 9.3 (2.8-31.2) if the patients had a new sex partner during the observation period.

Conclusions: The study shows that aggressive treatment of the patient with antibiotics combined with specific Lactobacillus strain administration and partner treatment can provide long lasting cure. A striking result of our study is that change of partner is strongly associated with relapse of BV.

Trial registration: ClinicalTrials.gov: NCT01245322.

Figures

Figure 1
Figure 1
Time schedule of the treatment and follow up. Even if the patient had a relapse at the self taken samples (3-6 months) she did not receive treatment until the clinical visit that determined with Amsel criteria at the clinical visit after 6 months.
Figure 2
Figure 2
Survival analysis with Life table showing the difference in cure rate between vaginal and oral administration of different Lactobacillus preparations. No statistical difference is seen. Group 0: EcoVag® capsule containing L. gasseri DSM 14869 and L. rhamnosus DSM 14870; Group 1: L. crispatus 4R5, L. gasseri 20M39, and L. jenseneii 22B42; Group 2: L. crispatus 23B33, L. gasseri 6M9, L. jenseneii 12B1; Group 3: L. crispatus 21M49, L. gasseri 6M9 and L. crispatus 8R6; Group 4: L. gasseri DSM 14869, L. rhamnosus DSM 14870 and L. gasseri DSM 15527; Group 5: Oral (the same group as the vaginal group 4) L. gasseri DSM 14869, L. rhamnosus DSM 14870, L. gasseri DSM 15527; Group 6: oral LaciBios® femina containing L. rhamnosus GR-1 and L. reuteri RC-14.
Figure 3
Figure 3
Survival analysis with Kaplan-Meier showing that there were significantly more relapses in patients who report a new sexual partner during follow up. Log rank < 0.001. Patients that are censored means that they have not completed the 24-month follow up. For some women the 24-month follow up is not done until 30 month. That is why some patients are reported as 30 month.

References

    1. Fredricks DN, Fiedler TL, Thomas KK, Oakley BB, Marrazzo JM. Targeted PCR for detection of vaginal bacteria associated with bacterial vaginosis. J Clin Microbiol. 2007;45(10):3270–3276. doi: 10.1128/JCM.01272-07.
    1. ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists, Number 72, May 2006: Vaginitis. Obstet Gynecol. 2006;107(5):1195–1206. doi: 10.1097/00006250-200605000-00049.
    1. Kane KY, Pierce R. What are the most effective treatments for bacterial vaginosis in nonpregnant women? J Fam Pract. 2001;50(5):399–400.
    1. Joesoef MR, Schmid G. Bacterial vaginosis. Clin Evid. 2004. pp. 2054–2063.
    1. Larsson PG, Forsum U. Bacterial vaginosis--a disturbed bacterial flora and treatment enigma. Apmis. 2005;113(5):305–316. doi: 10.1111/j.1600-0463.2005.apm_113501.x.
    1. Bradshaw CS, Morton AN, Hocking J, Garland SM, Morris MB, Moss LM, Horvath LB, Kuzevska I, Fairley CK. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis. 2006;193(11):1478–1486. doi: 10.1086/503780.
    1. Sobel JD, Ferris D, Schwebke J, Nyirjesy P, Wiesenfeld HC, Peipert J, Soper D, Ohmit SE, Hillier SL. Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. Am J Obstet Gynecol. 2006;194(5):1283–1289. doi: 10.1016/j.ajog.2005.11.041.
    1. Forsum U, Hallen A, Larsson PG. Bacterial vaginosis--a laboratory and clinical diagnostics enigma. Apmis. 2005;113(3):153–161. doi: 10.1111/j.1600-0463.2005.apm1130301.x.
    1. Vasquez A, Jakobsson T, Ahrne S, Forsum U, Molin G. Vaginal lactobacillus flora of healthy Swedish women. J Clin Microbiol. 2002;40(8):2746–2749. doi: 10.1128/JCM.40.8.2746-2749.2002.
    1. Zozaya-Hinchliffe M, Lillis R, Martin DH, Ferris MJ. Quantitative PCR assessments of bacterial species in women with and without bacterial vaginosis. J Clin Microbiol. 2010;48(5):1812–1819. doi: 10.1128/JCM.00851-09.
    1. Reid G, Charbonneau D, Erb J, Kochanowski B, Beuerman D, Poehner R, Bruce AW. Oral use of Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 significantly alters vaginal flora: randomized, placebo-controlled trial in 64 healthy women. FEMS Immunol Med Microbiol. 2003;35(2):131–134. doi: 10.1016/S0928-8244(02)00465-0.
    1. Anukam K, Osazuwa E, Ahonkhai I, Ngwu M, Osemene G, Bruce AW, Reid G. Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, double-blind, placebo controlled trial. Microbes Infect. 2006;8(6):1450–1454. doi: 10.1016/j.micinf.2006.01.003.
    1. Larsson PG, Stray-Pedersen B, Ryttig KR, Larsen S. Human lactobacilli as supplementation of clindamycin to patients with bacterial vaginosis reduce the recurrence rate; a 6-month, double-blind, randomized, placebo-controlled study. BMC Womens Health. 2008;8(1):3. doi: 10.1186/1472-6874-8-3.
    1. Ventura M, Zink R. Specific identification and molecular typing analysis of Lactobacillus johnsonii by using PCR-based methods and pulsed-field gel electrophoresis. FEMS Microbiol Lett. 2002;217(2):141–154. doi: 10.1111/j.1574-6968.2002.tb11468.x.
    1. Van Reenen CA, Dicks LM. Evaluation of numerical analysis of random amplified polymorphic DNA (RAPD)-PCR as a method to differentiate Lactobacillus plantarum and Lactobacillus pentosus. Curr Microbiol. 1996;32(4):183–187. doi: 10.1007/s002849900033.
    1. Torriani S, Zapparoli G, Dellaglio F. Use of PCR-based methods for rapid differentiation of Lactobacillus delbrueckii subsp. bulgaricus and L. delbrueckii subsp. lactis. Appl Environ Microbiol. 1999;65(10):4351–4356.
    1. Fitzsimons NA, Cogan TM, Condon S, Beresford T. Phenotypic and genotypic characterization of non-starter lactic acid bacteria in mature cheddar cheese. Appl Environ Microbiol. 1999;65(8):3418–3426.
    1. Song JY, Lin LL, Shott S, Kimber N, Tangora J, Cohen A, Wells A, Maezes M, Aroutcheva A, Faro S. Evaluation of the Strep B OIA test compared to standard culture methods for detection of group B streptococci. Infect Dis Obstet Gynecol. 1999;7(4):202–205.
    1. Jorgensen J, Turnidge J. In: Manual of Clinical Microbiology. 8. Murray P, Baron E, Jorgensen J, Pfaller M, Yolken R, editor. Washington, DC.: ASM Press; 2003. Susceptibility test methods: dilution and disk diffusion methods; pp. 1108–1125. Volume.
    1. Anukam KC, Osazuwa E, Osemene GI, Ehigiagbe F, Bruce AW, Reid G. Clinical study comparing probiotic Lactobacillus GR-1 and RC-14 with metronidazole vaginal gel to treat symptomatic bacterial vaginosis. Microbes Infect. 2006;8(12-13):2772–2776. doi: 10.1016/j.micinf.2006.08.008.
    1. Amsel R, Totten PA, Spiegel CA, Chen K, Eschenbach DA, Holmes KK. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med. 1983;74:14–22. doi: 10.1016/0002-9343(83)91112-9.
    1. Colli E, Landoni M, Parazzini F. Treatment of male partners and recurrence of bacterial vaginosis: a randomised trial. Genitourin Med. 1997;73(4):267–270.
    1. Eriksson K, Carlsson B, Forsum U, Larsson PG. A double-blind treatment study of bacterial vaginosis with normal vaginal lactobacilli after an open treatment with vaginal clindamycin ovules. Acta Derm Venereol. 2005;85(1):42–46. doi: 10.1080/00015550410022249.
    1. Hay PE, Lamont RF, Taylor-Robinson D, Morgan DJ, Ison C, Pearson J. Abnormal bacterial colonisation of the genital tract and subsequent preterm delivery and late miscarriage. Bmj. 1994;308(6924):295–298.
    1. Ison CA, Hay PE. Validation of a simplified grading of Gram stained vaginal smears for use in genitourinary medicine clinics. Sex Transm Infect. 2002;78(6):413–415. doi: 10.1136/sti.78.6.413.
    1. Koll P, Mandar R, Smidt I, Hutt P, Truusalu K, Mikelsaar RH, Shchepetova J, Krogh-Andersen K, Marcotte H, Hammarstrom L, Screening and Evaluation of Human Intestinal Lactobacilli for the Development of Novel Gastrointestinal Probiotics. Curr Microbiol. 2010.
    1. Wilson J. Managing recurrent bacterial vaginosis. Sex Transm Infect. 2004;80(1):8–11. doi: 10.1136/sti.2002.002733.
    1. Boris J, Pahlson C, Larsson PG. Six years observation after successful treatment of bacterial vaginosis. Infect Dis Obstet Gynecol. 1997;5(4):297–302.
    1. Marcone V, Calzolari E, Bertini M. Effectiveness of vaginal administration of Lactobacillus rhamnosus following conventional metronidazole therapy: how to lower the rate of bacterial vaginosis recurrences. New Microbiol. 2008;31(3):429–433.
    1. Marcone V, Rocca G, Lichtner M, Calzolari E. Long-term vaginal administration of Lactobacillus rhamnosus as a complementary approach to management of bacterial vaginosis. Int J Gynaecol Obstet. 2010;110(3):223–226. doi: 10.1016/j.ijgo.2010.04.025.
    1. Vaishnavi C. Established and potential risk factors for Clostridum difficile infection. Indian J Med Microbiol. 2009;27(4):289–300. doi: 10.4103/0255-0857.55436.
    1. Cook RL, Redondo-Lopez V, Schmitt C, Meriwether C, Sobel JD. Clinical, microbiological, and biochemical factors in recurrent bacterial vaginosis. J Clin Microbiol. 1992;30(4):870–877.
    1. Winceslaus SJ, Calver G. Recurrent bacterial vaginosis--an old approach to a new problem. Int J STD AIDS. 1996;7(4):284–287. doi: 10.1258/0956462961917816.
    1. Hay P. Recurrent Bacterial Vaginosis. Curr Infect Dis Rep. 2000;2(6):506–512. doi: 10.1007/s11908-000-0053-5.
    1. Hay P. Life in the littoral zone: lactobacilli losing the plot. Sex Transm Infect. 2005;81(2):100–102. doi: 10.1136/sti.2003.007161.
    1. Wilson JD, Shann SM, Brady SK, Mammen-Tobin AG, Evans AL, Lee RA. Recurrent bacterial vaginosis: the use of maintenance acidic vaginal gel following treatment. Int J STD AIDS. 2005;16(11):736–738. doi: 10.1258/095646205774763081.
    1. Sobel JD. Vulvovaginal candidosis. Lancet. 2007;369(9577):1961–1971. doi: 10.1016/S0140-6736(07)60917-9.
    1. Ehrstrom S, Daroczy K, Rylander E, Samuelsson C, Johannesson U, Anzen B, Pahlson C. Lactic acid bacteria colonization and clinical outcome after probiotic supplementation in conventionally treated bacterial vaginosis and vulvovaginal candidiasis. Microbes Infect. 2010;12(10):691–699. doi: 10.1016/j.micinf.2010.04.010.
    1. Falagas ME, Betsi GI, Athanasiou S. Probiotics for the treatment of women with bacterial vaginosis. Clin Microbiol Infect. 2007;13(7):657–664. doi: 10.1111/j.1469-0691.2007.01688.x.
    1. Antonio MA, Meyn LA, Murray PJ, Busse B, Hillier SL. Vaginal colonization by probiotic Lactobacillus crispatus CTV-05 is decreased by sexual activity and endogenous Lactobacilli. J Infect Dis. 2009;199(10):1506–1513. doi: 10.1086/598686.
    1. Burton JP, Cadieux PA, Reid G. Improved understanding of the bacterial vaginal microbiota of women before and after probiotic instillation. Appl Environ Microbiol. 2003;69(1):97–101. doi: 10.1128/AEM.69.1.97-101.2003.
    1. Gardiner GE, Heinemann C, Bruce AW, Beuerman D, Reid G. Persistence of Lactobacillus fermentum RC-14 and Lactobacillus rhamnosus GR-1 but not L. rhamnosus GG in the human vagina as demonstrated by randomly amplified polymorphic DNA. Clin Diagn Lab Immunol. 2002;9(1):92–96.
    1. Verstraelen H, Verhelst R, Vaneechoutte M, Temmerman M. The epidemiology of bacterial vaginosis in relation to sexual behaviour. BMC Infect Dis. p. 81.
    1. Potter J. Should sexual partners of women with bacterial vaginosis receive treatment? Br J Gen Pract. 1999;49(448):913–918.
    1. Vejtorp M, Bollerup AC, Vejtorp L, Fanoe E, Nathan E, Reiter A, Andersen ME, Stromsholt B, Schroder SS. Bacterial vaginosis: a double-blind randomized trial of the effect of treatment of the sexual partner. Br J Obstet Gynaecol. 1988;95(9):920–926. doi: 10.1111/j.1471-0528.1988.tb06581.x.
    1. Moi H, Erkkola R, Jerve F, Nelleman G, Bymose B, Alaksen K, Tornqvist E. Should male consorts of women with bacterial vaginosis be treated? Genitourin Med. 1989;65(4):263–268.
    1. Swedberg J, Steiner JF, Deiss F, Steiner S, Driggers DA. Comparison of single-dose vs one-week course of metronidazole for symptomatic bacterial vaginosis. Jama. 1985;254(8):1046–1049. doi: 10.1001/jama.254.8.1046.
    1. Heikkinen J, Vuopala S. Anaerobic vaginosis: treatment with tinidazole vaginal tablets. Gynecol Obstet Invest. 1989;28(2):98–100. doi: 10.1159/000293524.
    1. Mengel MB, Berg AO, Weaver CH, Herman DJ, Herman SJ, Hughes VL, Koepsell TD. The effectiveness of single-dose metronidazole therapy for patients and their partners with bacterial vaginosis. J Fam Pract. 1989;28(2):163–171.
    1. Sobel JD, Schmitt C, Meriwether C. Long-term follow-up of patients with bacterial vaginosis treated with oral metronidazole and topical clindamycin. J Infect Dis. 1993;167(3):783–784. doi: 10.1093/infdis/167.3.783.
    1. Schwebke JR, Desmond R. A randomized trial of metronidazole in asymptomatic bacterial vaginosis to prevent the acquisition of sexually transmitted diseases. Am J Obstet Gynecol. 2007;196(6):517 e511–516.
    1. Reichman O, Akins R, Sobel JD. Boric Acid Addition to Suppressive Antimicrobial Therapy for Recurrent Bacterial Vaginosis. Sex Transm Dis. 2009.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir